LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Jun 17 2011
0ShareAdd a commentRecommend PROVEXIS, the health supplements developer, reported deeper losses for the year to March 31, today alongside better revenues and the acquisition of a profitable sports nutrition manufacturer.

A 2.5m share placing will help fund the 8m takeover of Blackburn-based SiS (Science in Sport) which produces sports nutrition products for professional and elite athletes, including Olympians and professional cyclists and triathletes.

Provexis, which has a research and development (R&D) base in Liverpools Crown Street, benefited from the commercial launch of its first heart-health product, Fruitflow, in the UK and US.

Turnover rose from 14,767 to 50,086.

However, R&D costs increased from 718,468 to 1.26m, and while administrative costs were reined in from 1.18m to 1.27m, the company made a loss before tax of 2.34m compared with 1.7m last year.

However, chief executive Stephen Moon said the SiS acquisition will accelerate the groups development, with further acquisitions a possibility.

The revenue generating, profitable nature of the new business will help us to achieve our strategic goals, by adding a near term revenue stream to our longer-term pipeline development bias.

In the financial year to December 31 2010, SiS had an unaudited turnover of 4.6m compared with 4.3m in 2009 and an unaudited pre-tax profit of 200,000, against 400,000 the previous year.

Mr Moon said clinical trials for the companys Crohns disease treatment will expand with the opening of four new patient trial centres.

He said the Liverpool R&D team will also investigate the products potential for addressing the so-called superbug C.difficile.

And he said the company has agreed with DSM Nutritional Products, the firm licensed to market Fruitflow, to develop technology for the management of blood glucose.

He added: The management team will be focused on progress in the revenue generating areas of Fruitflow and SiS, while not losing sight of the medium and long term importance of the broader pipeline.

Cash management will continue to be an area of high importance. We will maintain our strategy of developing the capability of the overall Provexis team in line with our goals.

Provexis raised 2.5m in new shares in June and October last year and its cash balance at the end of its latest financial year stands at 7.6m, compared with 7m in 2010.


Read More http://www.liverpooldailypost.co.uk/liverpool-news/regional-news/2011/06/17/provexis-losses-deepen-but-profitable-acquisition-is-added-92534-28894657/#ixzz1PXUUw4wc

cynic your prediction about the plughole looks likely to be coming true.

'fraid so ..... it's total garbage

small read today,Bb, lol

thank you dc....lol not looking good, another seo....long wait.,.

I cannot help that, thats beyond me.

I'm doing my bit but theres only so much you can dlinkk iin aaaaaa ddaaayyyy,,,u undlsand.,.

Have you much invested here

25% of the max i'm prepared to put into a share so not hurting to bad. I hold over 100,000 shares.,.

Good for you. Link 1179 how many beers have you had. lol or That wine you won

you in this very deep??

i meant i buy fruitflow and enjoy it and also think it helps with the blood pressure.,.

No do not have any, will pass now. Just have a few xel, a lot of sou, rrl and xtr. Range will I hope bail the rest out, I hope.

Fruitflow

Who's taking up the new shares then????

Not another one you have put the mockers on bb

seems to be no stopping pxs right now - big resistance at 3p

Sssssh!!!

Down this goes once again on the news!!!!! What happened to the original 8p target then????? Mind you that was suggested in 2007!

MIDAS SHARE TIPS: Sports nutrition firm Provexis helped power our rowers to gold and now its shares could win bigBy Joanne Hart
PUBLISHED: 22:06, 4 August 2012 | UPDATED: 13:46, 5 August 2012
Comments (1) Share

..

Provexis is a sports nutrition and health food business with a difference. Using scientifically proven formulas to boost performance and improve health, the company’s products are used by GB Rowing, several Tour de France teams and hosts of other athletes – Olympians and enthusiasts alike.
The shares are just 1.5p but the company has recently been restructured and its performance should pick up significantly over the next 12 months and beyond.

Professional and amateur athletes spend nearly £20billion a year worldwide on sports nutrition, ranging from Lucozade to hydrating gels and energy tablets. In Britain alone, the market is worth £300million annually.


Golden girls: Heather Stanning and Helen Glover use Provexis products
For serious competitors, nutrition is an integral part of their preparation. In the Tour de France, cyclists consume about 7,000 calories a day and other endurance sports, such as rowing and marathon running, take similar tolls on the body. Trying to maintain energy levels in the face of such pressure is a big challenge.

Provexis takes a rigorous approach, using only natural ingredients to create powders, gels and drinks that are packed with proteins and carbohydrates to help athletes carry on for longer and recover faster.



The firm works with scientists and its products are held in high regard by the sporting community. Its relationship with the British rowing team, for which it is the official sports nutrition partner, dates back several years, and it works with leading cyclists, including Olympic road race winners Alexandre Vinokourov and Marianne Vos.

Provexis is not just about sporting nutrition, however. In fact, the company moved into this sector only last year, when chief executive Stephen Moon bought family business Science in Sport. Since that acquisition in June 2011, Moon has worked hard to improve the availability of Science in Sport’s products and boost productivity.




Provexis was spun out of Aberdeen University, where scientists were trying to understand why people in Mediterranean countries suffer fewer heart attacks than those in other nations.

After years of research, they concluded that the gel around tomato pips has special properties that help to prevent blood clots. The group developed a special extract, Fruitflow, which works in much the same way as aspirin but is entirely natural and has no harmful side-effects.
Developing the product was time-consuming and expensive so Provexis entered into a joint venture with Dutch conglomerate DSM, whose food division turns over £1.5billion a year. Selected sales of Fruitflow in syrup form have started but a tablet version is expected to go on sale soon. This has enormous potential.
More than 50million Americans take aspirin every day and consumption in Britain is extensive, too. If even a fraction of these move to natural, food-based pills instead, Provexis could see sales and profits soar.

The company reported full-year results last week, which showed a surge in turnover from £50,000 to £3.5million in the year to March 31. There was an underlying loss of £2.2million, reflecting investment in Fruitflow and restructuring costs as Moon took steps to streamline the business. But the group should move into profit over the next year or so.
Midas verdict: Provexis is a small company in a fast-growing sector. Moon, formerly at Lucozade-maker GlaxoSmithKline, is down to earth and determined. The past few years have been focused on development. The next few years are all set to be about sales and profits. Provexis should prove to be a winner. Buy.


Read more: http://www.thisismoney.co.uk/money/investing/article-2183743/MIDAS-SHARE-TIPS-Olympic-sports-nutrition-firm-Provexis-marks.html#ixzz22g8mkSlv